葡萄糖胺化学交换饱和转移(CEST)MRI用于乳腺癌成像:首次人体经验
这项前瞻性可行性研究纳入12例新诊断乳腺肿瘤患者,在3-T临床MRI扫描仪上采用葡萄糖胺(GlcN)CEST MRI成像,结果显示肿瘤组织信号高于周围乳腺组织(MTRasym效应8.12±4.09%,p=2.2E-03),GlcN摄取引起的增量增加为3.41±0.79%(p=2.2E-03),与T1W和T2W MRI显示的肿瘤位置一致。作者认为该初步可行性研究提示GlcN CEST MRI在临床环境中诊断乳腺癌的潜力。
要点
- GlcN CEST MRI可在不使用钆对比剂的情况下区分乳腺肿瘤与周围组织。
- 肿瘤组织MTRasym效应为8.12±4.09%,GlcN摄取引起的增量增加为3.41±0.79%。
- GlcN CEST可能用于识别代谢活跃的恶性乳腺肿瘤。
核心结论
- 这项初步可行性研究的结果提示GlcN CEST MRI在临床环境中诊断乳腺癌的潜力。
研究设计与样本
- 前瞻性IRB批准研究,2019年8月至2020年3月招募12例新诊断乳腺肿瘤患者(中位年龄53岁),所有MRI测量在3-T临床MRI扫描仪上完成;CEST成像采用脂肪抑制3D RF破坏梯度回波序列加饱和脉冲串。
关键影像表现/征象
- GlcN CEST MRI显示肿瘤组织信号强度高于周围乳腺组织,MTRasym效应为8.12±4.09%(N=12,p=2.2E-03)。
- GlcN摄取引起的增量增加为3.41±0.79%(N=12,p=2.2E-03),与T1W和T2W MRI显示的肿瘤位置一致。
- GlcN CEST谱包含对应自由水与羟基及酰胺/胺基团质子交换的不同峰,以及来自脂肪族基团的继发核Overhauser增强(NOE);GlcN摄取后肿瘤组织中各CEST积分平均增大倍数分别为2.2±1.2(p=3.38E-03)、1.4±0.4(p=9.88E-03)和1.6±0.6(p=2.09E-02)。
诊断标准与关键数值
- 基于磁化转移率不对称(MTRasym)和多高斯拟合在肿瘤及周围组织中定量CEST信号。
- 肿瘤组织MTRasym效应为8.12±4.09%(N=12,p=2.2E-03),GlcN摄取引起的增量增加为3.41±0.79%(N=12,p=2.2E-03)。
- GlcN摄取后肿瘤组织中各CEST积分平均增大倍数分别为2.2±1.2(p=3.38E-03)、1.4±0.4(p=9.88E-03)和1.6±0.6(p=2.09E-02)。
临床应用与阅片要点
- 作者认为GlcN CEST MRI方法可能用于在临床环境中检测乳腺癌,并应作为传统临床MRI方法的补充方法进行测试。
- 作者指出GlcN CEST成像可能用于识别代谢活跃的恶性乳腺肿瘤,且不使用钆对比剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to evaluate the feasibility of imaging breast cancer with glucosamine (GlcN) chemical exchange saturation transfer (CEST) MRI technique to distinguish between tumor and surrounding tissue, compared to the conventional MRI method.
METHODS: Twelve patients with newly diagnosed breast tumors (median age, 53 years) were recruited in this prospective IRB-approved study, between August 2019 and March 2020. Informed consent was obtained from all patients. All MRI measurements were performed on a 3-T clinical MRI scanner. For CEST imaging, a fat-suppressed 3D RF-spoiled gradient echo sequence with saturation pulse train was applied. CEST signals were quantified in the tumor and in the surrounding tissue based on magnetization transfer ratio asymmetry (MTRasym) and a multi-Gaussian fitting.
RESULTS: GlcN CEST MRI revealed higher signal intensities in the tumor tissue compared to the surrounding breast tissue (MTRasym effect of 8.12 ± 4.09%, N = 12, p = 2.2 E-03) with the incremental increase due to GlcN uptake of 3.41 ± 0.79% (N = 12, p = 2.2 E-03), which is in line with tumor location as demonstrated by T1W and T2W MRI. GlcN CEST spectra comprise distinct peaks corresponding to proton exchange between free water and hydroxyl and amide/amine groups, and relayed nuclear Overhauser enhancement (NOE) from aliphatic groups, all yielded larger CEST integrals in the tumor tissue after GlcN uptake by an averaged factor of 2.2 ± 1.2 (p = 3.38 E-03), 1.4 ± 0.4 (p =9.88 E-03), and 1.6 ± 0.6 (p = 2.09 E-02), respectively.
CONCLUSION: The results of this initial feasibility study indicate the potential of GlcN CEST MRI to diagnose breast cancer in a clinical setup.
KEY POINTS: • GlcN CEST MRI method is demonstrated for its the ability to differentiate between breast tumor lesions and the surrounding tissue, based on the differential accumulation of the GlcN in the tumors. • GlcN CEST imaging may be used to identify metabolic active malignant breast tumors without using a Gd contrast agent. • The GlcN CEST MRI method may be considered for use in a clinical setup for breast cancer detection and should be tested as a complementary method to conventional clinical MRI methods.
引用
- Rivlin, Anaby, Nissan, et al. Breast cancer imaging with glucosamine CEST (chemical exchange saturation transfer) MRI: first human experience. Eur Radiol. 2022. PMID: 35420304. doi:10.1007/s00330-022-08772-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。